Shogo Urabe
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Shogo Urabe has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Kenji Kashima
Research Division, Chugai Pharmaceutical Co. Ltd., Kanagawa, Japan
2 shared publications - Masuho Saburi
Department of Hematology Oita Prefectural Hospital Oita Japan
2 shared publications A. Hisamatsu
Department of General Medicine and Gastroenterology, Faculty of Medicine, Oita University, Yufu, Japan
1 shared publicationEiichi Ohtsuka
Department of Hematology, Oita Prefectural Hospital, Oita, Japan
1 shared publication- Eiichi Ohtsuka
Department of Hematology Oita Prefectural Hospital Oita Japan
1 shared publication Katsuya Kawano
Department of Clinical Laboratory Technology, Oita Prefectural Hospital, Oita, Japan
1 shared publication
Latest Publications
- Open Access
- 16 September 2025
- Published by Wiley in Cancer Reports
- Vol. 8 (9) , e70349
Disease Control and Manageable Toxicity With Epcoritamab in Refractory Diffuse Large B‐Cell Lymphoma‐Type Richter Syndrome: A Case Report in an Elderly Patient
Background: Richter syndrome (RS) is an aggressive transformation of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) with poor prognosis. No standard treatment for RS has been established. Epcoritamab, a CD3xCD20 bispecific antibody, may offer clinical benefit.Case: An 80‐year‐old woman was diagnosed with SLL in 2017 and remained untreated for nearly 6 years. In 2023, she developed a bulky abdominal tumor. Although the initial biopsy showed SLL progression without transformation, subsequent treatments with acalabrutinib, venetoclax plus rituximab, and bendamustine plus rituximab failed. In 2024, transformation to diffuse large B‐cell lymphoma‐type RS (DLBCL‐RS) was confirmed. Two lines of cytotoxic regimens were ineffective, with rapid tumor growth. Epcoritamab was initiated as third‐line therapy. Grade 1–3 cytokine release syndrome occurred but resolved with standard management. No neurotoxicity was observed. Partial response (PR) was achieved by week 12, and the patient has maintained PR for 10 months. Infections including COVID‐19 and cytomegalovirus were managed successfully, and immunoglobulin replacement was introduced for hypogammaglobulinemia.Conclusion: This case highlights the potential of epcoritamab as an important treatment option for elderly patients with refractory DLBCL‐RS.
- 16 September 2025
- Published by Wiley in Cancer Reports
- Vol. 8 (9) , e70349
Open AccessDisease Control and Manageable Toxicity With Epcoritamab in Refractory Diffuse Large B‐Cell Lymphoma‐Type Richter Syndrome: A Case Report in an Elderly Patient
Background: Richter syndrome (RS) is an aggressive transformation of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) with poor prognosis. No standard treatment for RS has been established. Epcoritamab, a CD3xCD20 bispecific antibody, may offer clinical benefit.Case: An 80‐year‐old woman was diagnosed with SLL in 2017 and remained untreated for nearly 6 years. In 2023, she developed a bulky abdominal tumor. Although the initial biopsy showed SLL progression without transformation, subsequent treatments with acalabrutinib, venetoclax plus rituximab, and bendamustine plus rituximab failed. In 2024, transformation to diffuse large B‐cell lymphoma‐type RS (DLBCL‐RS) was confirmed. Two lines of cytotoxic regimens were ineffective, with rapid tumor growth. Epcoritamab was initiated as third‐line therapy. Grade 1–3 cytokine release syndrome occurred but resolved with standard management. No neurotoxicity was observed. Partial response (PR) was achieved by week 12, and the patient has maintained PR for 10 months. Infections including COVID‐19 and cytomegalovirus were managed successfully, and immunoglobulin replacement was introduced for hypogammaglobulinemia.Conclusion: This case highlights the potential of epcoritamab as an important treatment option for elderly patients with refractory DLBCL‐RS.
- 26 October 2021
- Published by Springer Nature in International Journal of Hematology
- Vol. 115 (4) , 585-589
Successful treatment with tirabrutinib for relapsed lymphoplasmacytic lymphoma complicated by Bing–Neel syndrome
A 53-year-old woman was diagnosed with lymphoplasmacytic lymphoma (LPL)/Waldenström's macroglobulinemia (WM) in 2008. Six courses of R-COP (rituximab, cyclophosphamide, vincristine, and prednisolone) resulted in complete remission, but LPL/WM relapsed in 2015. After six courses of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone), the M-peak disappeared, but the patient presented with muscle weakness and sensory disturbance in the lower extremities. No lesions were apparent in the brain parenchyma, but T2-weighted magnetic resonance imaging (MRI) showed a signal-hyperintense area with contrast enhancement in the spinal cord at the C2–4 and Th2–3 levels, and cerebrospinal fluid (CSF) examination showed only a few mononuclear cells. In 2020, the patient started to require walking assistance, and MRI findings worsened. Neurologically, lower limb muscle strength was reduced (manual muscle test score 3), and sensations of touch and pain were about 30% of normal. Vibratory sensation was absent at the knees and medial malleoli, accompanied by dysuria due to neurogenic bladder. CSF cell count was 15/μl (all mononuclear cells). Bing–Neel syndrome (BNS) was diagnosed and tirabrutinib was started. Within 2 months of treatment, lower extremity muscle strength had normalized and MRI findings had improved. Tirabrutinib may offer a promising therapeutic option for BNS.
- 26 October 2021
- Published by Springer Nature in International Journal of Hematology
- Vol. 115 (4) , 585-589
Successful treatment with tirabrutinib for relapsed lymphoplasmacytic lymphoma complicated by Bing–Neel syndrome
A 53-year-old woman was diagnosed with lymphoplasmacytic lymphoma (LPL)/Waldenström's macroglobulinemia (WM) in 2008. Six courses of R-COP (rituximab, cyclophosphamide, vincristine, and prednisolone) resulted in complete remission, but LPL/WM relapsed in 2015. After six courses of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone), the M-peak disappeared, but the patient presented with muscle weakness and sensory disturbance in the lower extremities. No lesions were apparent in the brain parenchyma, but T2-weighted magnetic resonance imaging (MRI) showed a signal-hyperintense area with contrast enhancement in the spinal cord at the C2–4 and Th2–3 levels, and cerebrospinal fluid (CSF) examination showed only a few mononuclear cells. In 2020, the patient started to require walking assistance, and MRI findings worsened. Neurologically, lower limb muscle strength was reduced (manual muscle test score 3), and sensations of touch and pain were about 30% of normal. Vibratory sensation was absent at the knees and medial malleoli, accompanied by dysuria due to neurogenic bladder. CSF cell count was 15/μl (all mononuclear cells). Bing–Neel syndrome (BNS) was diagnosed and tirabrutinib was started. Within 2 months of treatment, lower extremity muscle strength had normalized and MRI findings had improved. Tirabrutinib may offer a promising therapeutic option for BNS.
- 1 December 2012
- Published by Elsevier in Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
- Vol. 114 (6) , e43-e48
α-amylase crystalloid granuloma of the parotid gland: case report and review of the literature
- 1 December 2012
- Published by Elsevier in Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
- Vol. 114 (6) , e43-e48
α-amylase crystalloid granuloma of the parotid gland: case report and review of the literature
- Open Access
- 10 February 2012
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 44 (S 02) , E246-E247
A case of Good syndrome with refractory gastrointestinal ulcers
A 61-year-old woman was referred to our hospital in November 2011 for treatment of chronic diarrhea and refractory gastrointestinal ulcers. Her medical history included thymoma (resected at age 44) accompanied by hypogammaglobulinemia and pure red cell aplasia (PRCA), and a distal gastrectomy for gastric ulcer (refractory to proton pump inhibitor treatment and Helicobacter pylori eradication). On the patient’s admission, laboratory examination revealed severe hypogammaglobulinemia, absence of peripheral B cells, CD4+ T-cell lymphopenia, and inverted CD4 /CD8+ T-cell ratio. Pathogenic bacteria, cytomegalovirus, and human immunodeficiency virus tests were negative. From these results and her medical history, the patient was diagnosed with Good syndrome with PRCA, and was treated with intravenous immune globulin (IVIG) every 2 weeks. At 2 months later, her immune globulin level had increased to normal. Previously upper and lower gastrointestinal endoscopy had shown an ulcer at the greater curvature ([Fig. 1 a]), and similar multiple ulcers at the ileocecum and the terminal ileum on admission ([Fig. 1 c]). Histopathological analysis of the biopsy specimens from these lesions showed a lack of plasma cells in the lamina propria, epithelial apoptosis, and increased intraepithelial lymphocytes (IELs) ([Fig. 2]). Similarly, 2 months after initiation of IVIG treatment, these lesions were markedly improved ([Fig. 1 b, d]), and the epithelial apoptosis and IELs had disappeared. Good syndrome is defined as thymoma with adult-onset immunodeficiency, and is characterized by hypogammaglobulinemia, low or absent B-cells, CD4+ T-cell lymphopenia, and inverted CD4/CD8+ T-cell ratio [1]. Although diarrhea is the main gastrointestinal manifestation of the syndrome, in most cases no definite pathogens are identified [2]. A lack of plasma cells in the lamina propria, epithelial apoptosis, and increased IELs are characteristic histopathological findings in common variable immunodeficiency, a primary immunodeficiency similar to Good syndrome [3] [4], but not in Good syndrome. This is the first report in English describing endoscopic and pathological improvement of refractory gastrointestinal ulcers in Good syndrome by IVIG treatment. Endoscopy_UCTN_Code_CCL_1AB_2AD_3AC
- 10 February 2012
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 44 (S 02) , E246-E247
Open AccessA case of Good syndrome with refractory gastrointestinal ulcers
A 61-year-old woman was referred to our hospital in November 2011 for treatment of chronic diarrhea and refractory gastrointestinal ulcers. Her medical history included thymoma (resected at age 44) accompanied by hypogammaglobulinemia and pure red cell aplasia (PRCA), and a distal gastrectomy for gastric ulcer (refractory to proton pump inhibitor treatment and Helicobacter pylori eradication). On the patient’s admission, laboratory examination revealed severe hypogammaglobulinemia, absence of peripheral B cells, CD4+ T-cell lymphopenia, and inverted CD4 /CD8+ T-cell ratio. Pathogenic bacteria, cytomegalovirus, and human immunodeficiency virus tests were negative. From these results and her medical history, the patient was diagnosed with Good syndrome with PRCA, and was treated with intravenous immune globulin (IVIG) every 2 weeks. At 2 months later, her immune globulin level had increased to normal. Previously upper and lower gastrointestinal endoscopy had shown an ulcer at the greater curvature ([Fig. 1 a]), and similar multiple ulcers at the ileocecum and the terminal ileum on admission ([Fig. 1 c]). Histopathological analysis of the biopsy specimens from these lesions showed a lack of plasma cells in the lamina propria, epithelial apoptosis, and increased intraepithelial lymphocytes (IELs) ([Fig. 2]). Similarly, 2 months after initiation of IVIG treatment, these lesions were markedly improved ([Fig. 1 b, d]), and the epithelial apoptosis and IELs had disappeared. Good syndrome is defined as thymoma with adult-onset immunodeficiency, and is characterized by hypogammaglobulinemia, low or absent B-cells, CD4+ T-cell lymphopenia, and inverted CD4/CD8+ T-cell ratio [1]. Although diarrhea is the main gastrointestinal manifestation of the syndrome, in most cases no definite pathogens are identified [2]. A lack of plasma cells in the lamina propria, epithelial apoptosis, and increased IELs are characteristic histopathological findings in common variable immunodeficiency, a primary immunodeficiency similar to Good syndrome [3] [4], but not in Good syndrome. This is the first report in English describing endoscopic and pathological improvement of refractory gastrointestinal ulcers in Good syndrome by IVIG treatment. Endoscopy_UCTN_Code_CCL_1AB_2AD_3AC